Interest in biomarkers has exploded in recent years, driven by improvements in data collection and analysis, burgeoning interest in personalized medicine, and efforts to increase the success rate for ...
Protein biomarkers increasingly play a vital role in advancing health research, driving drug development, and improving clinical outcomes. The close connection between protein biomarkers and human ...
Every decision in drug development carries weight. The right biomarker insights can make those decisions more confident and data-driven. In this white paper, experts from AstraZeneca, Johnson & ...
Neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, and other related disorders, represent a ...
Drug development involves significant risk and expense. With average development costs topping $1 billion per approved medicine and stubbornly high failure rates, pharmaceutical leaders are ...
Medicaid Expansion and Stage at Diagnosis, Timely Initiation and Receipt of Guideline-Concordant Treatment, and Survival Among People With Non–Small Cell Lung Cancer The CHAI platform extracted ...
Tuberculosis (TB) remains one of the world's most serious public health threats, with approximately one-quarter of the global ...
The integration of proteomics in biomarker discovery represents a major advancement in molecular diagnostics and precision medicine. Researchers seek highly specific indicators of complex disease ...
Bridging Discovery with Clinical Practice: Biomarkers for Early Detection in Diabetic Kidney Disease
Diabetic kidney disease (DKD) is a major microvascular complication of diabetes and remains the leading cause of end-stage renal disease (ESRD) worldwide.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results